High Rupee Hurts Dr. Reddy Profit; Cipla's Net Rises (India)
This article was originally published in PharmAsia News
Executive Summary
Dr. Reddy's Laboratories Ltd. reports fiscal second-quarter net profit fell 4.5 percent, while Cipla Ltd. says its net profit rose 6.1 percent and forecast a difficult fiscal year coming up. Both firms were affected by the rising rupee. Dr. Reddy's consolidated net profit fell to 2.67 billion rupees ($67.4 million) for the period ended Sept. 30 from 2.8 billion rupees a year earlier, which was boosted by high-margin authorized generic drugs and product exclusivity. Besides the rupee, which has increased more than 10 percent against the dollar since January, Dr. Reddy's blamed costs and revenue from its Betapharm unit, which it acquired last year, for its weak performance. Cipla's net profit rose to 1.91 billion rupees from 1.80 billion rupees, with net sales increasing 23 percent to 10.98 billion rupees. "I will not be too optimistic about the next two quarters," said Joint Managing Director Amar Lulla. "Achieving an annual growth rate of 12 percent to 15 percent will be difficult given the way the rupee is appreciating." (Click here for more - May Require Paid Subscription
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.